Health is everyone’s business has been saved
Close
Health equity’s economic impact | Deloitte Insights
The Deloitte Center for Health Solutions’ latest analysis reveals how businesses can benefit from a healthier, more productive workforce and contribute to a more equitable society.
false
.jpg)
Close
Global divestiture survey
The potential value of a divestiture goes beyond its transaction price. Our latest Global Corporate Divestiture Survey shows that organizations who approach divestiture planning in earnest can lower their separation cost and effort, increase transaction value, and realize growth and optimization opportunities for the divesting organization. Read more.
false
.jpg)
Close
How embracing AI in M&A can drive exponential value
As organizations build toward their brightest future, AI in M&A is a vital component. So is acting early. GenAI’s impact on processes throughout the deal life cycle and the growing use of mergers, acquisitions, and divestitures to improve AI capabilities are among the key trends taking shape. Read more.
false
Close
2024 Life Sciences Industry Accounting Guide | Deloitte US
Accounting in life sciences is ever-evolving, with new challenges surfacing and business priorities shifting every day. Deloitte’s 2024 Life Sciences Industry Accounting Guide can help accounting teams address the unique set of issues they face.
false
Close
2024 Health Tech Industry Accounting Guide | Deloitte US
The health tech industry (or the converging technology and health care and life sciences industry) encompasses a wide spectrum of technology and service solution providers, each with their own unique set of accounting issues. The 2024 Health Tech Industry Accounting Guide offers insight into these issues—giving health tech accounting professionals the practical guidance they need to navigate the complexities they face.
false
Close
New accounting rule for life sciences/pharma R&D funding | Deloitte US
FASB has proposed a new accounting standard that could change the way life sciences companies account for R&D funding arrangements. If finalized, it would simplify accounting for many life sciences R&D funding arrangements by excluding them from the derivative account model. These changes could lead to an uptick in the number of life sciences R&D funding arrangements.
false
Close
Life sciences IPO readiness: Insights for early-stage companies | Deloitte US
Early-stage life sciences companies can get ready to go public by bolstering essential skill sets and capabilities. Closing, forecasting, and implementing more robust enterprise resource planning (ERP) systems that can scale with the business should be a priority. A number of technical accounting skills and considerations can also come into play.
false
Close
Femtech Growth and Investment Opportunities | Deloitte US
The femtech market, which focuses on women’s health technology, is gaining momentum. Historical lack of investment has impeded women’s health care solutions, including femtech, but things are beginning to change. Deloitte can advise femtech entrepreneurs on funding strategies and audit and assurance services.
false
Close
Deloitte at CES 2025 | January 7-10, 2025 | Las Vegas, NV
See what’s in store for Deloitte at CES 2025. Join us to learn more about a wide array of topics, from the revolutionary forces reshaping health and entertainment to the critical integration of privacy in product development.
false
Close
Is Generative AI Changing the Game for Medtech? | Deloitte US
Dive into the transformative impacts of artificial intelligence (AI) and Generative Artificial Intelligence (GenAI) in the evolving medtech landscape. Our report takes an in-depth look at how these technologies are reshaping the industry, delivering value, and setting the stage for further advancements.
false
